Ms. Jenn Hepburn reports

EMERALD HEALTH THERAPEUTICS CLOSES $2.1 MILLION PROSPECTUS SALE

Emerald Health Therapeutics Inc. has closed its prospectus offering to certain institutional accredited investors, as announced on May 21, 2020. Pursuant to the offering, Emerald has issued 11,351,351 units of Emerald at a price of 18.5 cents per unit for total gross proceeds of $2.1-million.

Each unit consists of one common share of Emerald and one common share purchase warrant. Each warrant entitles the investors to acquire one additional common share at a price of 27 cents per warrant share for a period of three years following the closing of the offering. In the event that the closing sale price of the common shares on the TSX Venture Exchange, or such other principal exchange on which the common shares are then trading, is greater than 40 cents per common share for a period of 10 consecutive trading days at any time after the closing of the offering, Emerald may accelerate the expiry date of the warrants by giving written notice to the investors and in such case the warrants will expire on the 15th day after the date on which such notice is given by Emerald.

Emerald intends to use the net proceeds of the offering for the payment of salaries, lease obligations and other operating costs. The units were offered by way of a shelf prospectus supplement filed in all of the provinces of Canada pursuant to National Instrument 44-102 -- Shelf Distributions.

About Emerald Health Therapeutics

Emerald Health is committed to cutting-edge cannabis science to create new consumer experiences with distinct recreational, medical and wellness-oriented cannabis and non-cannabis products. With an emphasis on innovation and production excellence, Emerald's three distinct operating assets are designed to uniquely serve the Canadian marketplace and international opportunities.

We seek Safe Harbor.